Loading...
XNAS
OABI
Market cap228mUSD
Jul 07, Last price  
1.87USD
1D
-3.11%
1Q
-1.84%
IPO
-80.84%
Name

Avista Public Acquisition Corp II

Chart & Performance

D1W1MN
P/E
P/S
8.67
EPS
Div Yield, %
Shrs. gr., 5y
-2.27%
Rev. gr., 5y
7.58%
Revenues
26m
-22.75%
18,318,00023,268,00034,748,00059,077,00034,164,00026,391,000
Net income
-62m
L+22.55%
-13,589,000-17,557,000-27,042,000-22,334,000-50,619,000-62,033,000
CFO
-40m
L
-5,195,0003,619,000-5,672,000-3,587,0002,347,000-39,664,000
Earnings
Aug 06, 2025

Profile

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
IPO date
Oct 09, 2020
Employees
95
Domiciled in
US
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
26,391
-22.75%
34,164
-42.17%
59,077
70.02%
Cost of revenue
85,851
89,838
89,517
Unusual Expense (Income)
NOPBT
(59,460)
(55,674)
(30,440)
NOPBT Margin
Operating Taxes
(9,378)
(13,744)
(3,727)
Tax Rate
NOPAT
(50,082)
(41,930)
(26,713)
Net income
(62,033)
22.55%
(50,619)
126.65%
(22,334)
-17.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,369
(592)
96,488
BB yield
-3.14%
0.10%
-31.41%
Debt
Debt current
3,782
6,972
1,780
Long-term debt
42,546
47,636
49,812
Deferred revenue
862
4,325
Other long-term liabilities
1,156
3,233
4,135
Net debt
(13,106)
(32,375)
(37,122)
Cash flow
Cash from operating activities
(39,664)
2,347
(3,587)
CAPEX
(1,875)
(1,644)
(17,168)
Cash from investing activities
37,884
(18,376)
(73,313)
Cash from financing activities
13,020
(892)
110,739
FCF
(45,230)
(26,158)
(44,096)
Balance
Cash
59,434
86,983
88,265
Long term investments
449
Excess cash
58,114
85,275
85,760
Stockholders' equity
(101,361)
(39,305)
11,273
Invested Capital
413,299
387,032
360,871
ROIC
ROCE
EV
Common stock shares outstanding
102,365
99,683
85,318
Price
3.54
-42.63%
6.17
71.39%
3.60
-64.00%
Market cap
362,372
-41.08%
615,044
100.25%
307,145
-62.82%
EV
349,266
582,669
270,023
EBITDA
(35,877)
(36,177)
(12,191)
EV/EBITDA
Interest
587
Interest/NOPBT